Form D · Biotechnology
Alexo Therapeutics Ltd
Dublin 2, L2 · CIK 0001642930
Offering snapshot reported May 21, 2015 · SEC filing
- Reported sold
- $18M Offering amount: $36M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $37.5K Reported outside-investor minimum
- First sale
- May 8, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 21, 2015 | Initial | $18,022,500 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-240360
Source: Form D, filed May 21, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| N/A Bradwell Limited | Executive |
| Corey Goodman | Director |
| Jason Lettman | Director |
| Jaume Pons | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Bradwell Limited Arthur Cox Building, Earlsfort Terrace
Dublin 2, L2, 000000
Dublin 2, L2, 000000